fStAx-35R TFA is the drocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research.
References:
[1]. Cui HK, et al., Design of stapled α-helical peptides to specifically activate Wnt/β-catenin signaling. Cell Res. 2013 Apr;23(4):581-4.
















